Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Harding

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Ophthalmic Research|January 1, 1996
The influence of some post-translational modifications on the chaperone-like activity of alpha-crystallinM A van Boekel, S E Hoogakker, J J Harding, et al.
Protein Science : a Publication of the Protein Society|April 1, 1997
Amino acid sequence of bovine gamma E (IVa) lens crystallinG W Kilby, M M Sheil, D Shaw, et al.
Current Eye Research|July 27, 1999
Sugars including erythronic and threonic acids in human aqueous humourJ J Harding, P C Hassett, K C Rixon, et al.
Mechanisms of Ageing and Development|October 1, 1989
Non-enzymic post-translational modification of proteins in aging. A reviewJ J Harding, H T Beswick, R Ajiboye, et al.
Ophthalmic Research|January 1, 1996
Molecular masses of gamma-crystallinsM L Riley, J J Harding, G W Kilby, et al.
The British Journal of Ophthalmology|June 30, 2000
The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritinA D Mumford, I A Cree, J D Arnold, et al.
Biochimica Et Biophysica Acta|December 17, 2009
Investigation of gammaE-crystallin target protein binding to bovine lens alpha-crystallin by small-angle neutron scatteringM J Clarke, J B Artero, M Moulin, et al.
European Journal of Biochemistry|February 13, 2001
Chaperone function of mutant versions of alpha A- and alpha B-crystallin prepared to pinpoint chaperone binding sitesB K Derham, M A van Boekel, P J Muchowski, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Ophthalmic Research|January 1, 1996
The influence of some post-translational modifications on the chaperone-like activity of alpha-crystallinM A van Boekel, S E Hoogakker, J J Harding, et al.
Protein Science : a Publication of the Protein Society|April 1, 1997
Amino acid sequence of bovine gamma E (IVa) lens crystallinG W Kilby, M M Sheil, D Shaw, et al.
Current Eye Research|July 27, 1999
Sugars including erythronic and threonic acids in human aqueous humourJ J Harding, P C Hassett, K C Rixon, et al.
Mechanisms of Ageing and Development|October 1, 1989
Non-enzymic post-translational modification of proteins in aging. A reviewJ J Harding, H T Beswick, R Ajiboye, et al.
Ophthalmic Research|January 1, 1996
Molecular masses of gamma-crystallinsM L Riley, J J Harding, G W Kilby, et al.
The British Journal of Ophthalmology|June 30, 2000
The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritinA D Mumford, I A Cree, J D Arnold, et al.
Biochimica Et Biophysica Acta|December 17, 2009
Investigation of gammaE-crystallin target protein binding to bovine lens alpha-crystallin by small-angle neutron scatteringM J Clarke, J B Artero, M Moulin, et al.
European Journal of Biochemistry|February 13, 2001
Chaperone function of mutant versions of alpha A- and alpha B-crystallin prepared to pinpoint chaperone binding sitesB K Derham, M A van Boekel, P J Muchowski, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Pageof 14